REVELATION BIOSCIENCES, INC. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest
REVELATION BIOSCIENCES, INC. (REVB) reported Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest of -$2.13 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-15.
Discontinued › Shareholders' Equity
us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest · last filed 2022-04-15
- REVELATION BIOSCIENCES, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-12-31 was -$1.21M.
- REVELATION BIOSCIENCES, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-09-30 was -$759.49K.
- REVELATION BIOSCIENCES, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-06-30 was -$1.33M.
- REVELATION BIOSCIENCES, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-03-31 was $1.17M.
- REVELATION BIOSCIENCES, INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2021 was -$2.13M.
| Period end | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | -$1.97M derived: sum of 2 quarters · filed 2022-04-15 | -$3.30M derived: sum of 3 quarters · filed 2022-04-15 | -$2.13M 10-K · filed 2022-04-15 |
| 2021-09-30 | -$759.49K 10-Q · filed 2021-10-29 | -$2.09M derived: sum of 2 quarters · filed 2021-10-29 | -$916.31K 10-Q · filed 2021-10-29 | |
| 2021-06-30 | -$1.33M 10-Q · filed 2021-08-23 | -$152.95K 10-Q · filed 2021-08-23 | ||
| 2021-03-31 | $1.17M derived: 10-K 12 month − 3 quarters · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |